Protalix Biotherapeutics (NYSEAMERICAN:PLX) received a $5.00 price target from HC Wainwright in a research report issued on Thursday. The brokerage presently has a “buy” rating on the stock.

A number of other analysts have also issued reports on PLX. Zacks Investment Research lowered Protalix Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, December 20th. BidaskClub lowered Protalix Biotherapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, December 2nd.

Protalix Biotherapeutics (PLX) opened at $0.74 on Thursday. Protalix Biotherapeutics has a 1 year low of $0.38 and a 1 year high of $1.51. The firm has a market capitalization of $320.34, a price-to-earnings ratio of -0.37 and a beta of 0.98.

Protalix Biotherapeutics (NYSEAMERICAN:PLX) last posted its quarterly earnings data on Wednesday, November 8th. The company reported ($0.09) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by ($0.04). The business had revenue of $7.53 million during the quarter, compared to analyst estimates of $6.65 million. During the same quarter in the prior year, the company posted ($0.07) earnings per share.

A hedge fund recently bought a new stake in Protalix Biotherapeutics stock. OxFORD Asset Management LLP bought a new stake in shares of Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 687,796 shares of the company’s stock, valued at approximately $576,000. OxFORD Asset Management LLP owned 0.54% of Protalix Biotherapeutics at the end of the most recent reporting period.

WARNING: This report was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another domain, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this report can be accessed at

About Protalix Biotherapeutics

Protalix BioTherapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers taliglucerase alfa for injection, which is an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease.

Receive News & Ratings for Protalix Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix Biotherapeutics and related companies with's FREE daily email newsletter.